SCHEMBL679474

SCHEMBL679474

Cn1ncc2cc(Oc3ccc([N+](=O)[O-])cc3F)c(NC(=O)O)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
MAPT P10636 3/20 0.44
MAPK1 P28482 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
S1PR4 O95977 1/20 0.42
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
POLB P06746 2/20 0.41
NPC1 O15118 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
LMNA P02545 4/20 0.40
HSPB1 P04792 2/20 0.40
HPGD P15428 2/20 0.40
PLK4 O00444 1/20 0.40
NTRK1 P04629 1/20 0.40
RET P07949 1/20 0.40
MET P08581 1/20 0.40
AXL P30530 1/20 0.40
KDR P35968 1/20 0.40
FLT3 P36888 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679110 0.86 SERPINE1 (0.43) ALDH1A1MAPTMAPK1L3MBTL1S1PR4
SCHEMBL680681 0.84 CACNA1H (0.42) PLK4NTRK1RETMETAXL
SCHEMBL678989 0.83 MAPT (0.44) ALDH1A1MAPTL3MBTL1S1PR4PKM
SCHEMBL679255 0.83 HSPB1 (0.44) ALDH1A1MAPTMAPK1L3MBTL1S1PR4
SCHEMBL29487166 0.83 HSPB1 (0.44) ALDH1A1MAPTMAPK1L3MBTL1S1PR4
SCHEMBL680051 0.82 RXRA (0.42) ALDH1A1MAPTMAPK1L3MBTL1S1PR4
SCHEMBL680514 0.80 PLK4 (0.41) ALDH1A1MAPTMAPK1L3MBTL1S1PR4
SCHEMBL679209 0.79 ALDH1A1 (0.39) ALDH1A1MAPTMAPK1L3MBTL1S1PR4
SCHEMBL679247 0.78 CYP11B1 (0.47) ALDH1A1MAPTMAPK1L3MBTL1S1PR4
SCHEMBL23081442 0.78 CCNT1 (0.42) ALDH1A1MAPTMAPK1L3MBTL1S1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC ALDH1A1 1450/4885MAPT 4502/4885MAPK1 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.